بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
increase » increased (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
linear decrease » linear increase (توسيع البحث)
increase » increased (توسيع البحث)
-
561
-
562
-
563
-
564
-
565
-
566
-
567
BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma.
منشور في 2024الموضوعات: -
568
-
569
-
570
Data Sheet 1_Mycobacterium tuberculosis infection may increase the degrees of malignancy in lung adenocarcinoma.docx
منشور في 2025"…</p>Conclusion<p>Our findings suggest that MTB infection may increase the malignancy of LAC, with the pronounced expression of PD-L1 in granuloma regions constituting a pivotal mechanism underlying this relationship.…"
-
571
-
572
Semiannual analysis of monthly use of skin disinfection swab sets in the hospital.
منشور في 2024الموضوعات: -
573
-
574
-
575
-
576
-
577
-
578
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
579
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
580
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"